These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 11790161)

  • 1. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
    McKeage K; Perry CM
    Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of trastuzumab.
    Jones RL; Smith IE
    Expert Opin Drug Saf; 2004 Jul; 3(4):317-27. PubMed ID: 15268649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
    N Engl J Med; 2001 Mar; 344(11):783-92. PubMed ID: 11248153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
    Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ; Press M
    J Clin Oncol; 2002 Feb; 20(3):719-26. PubMed ID: 11821453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development and clinical use of trastuzumab (Herceptin).
    Harries M; Smith I
    Endocr Relat Cancer; 2002 Jun; 9(2):75-85. PubMed ID: 12121832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From HER2 to herceptin.
    Mokbel K; Hassanally D
    Curr Med Res Opin; 2001; 17(1):51-9. PubMed ID: 11464447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
    Gori S; Colozza M; Mosconi AM; Franceschi E; Basurto C; Cherubini R; Sidoni A; Rulli A; Bisacci C; De Angelis V; Crinò L; Tonato M
    Br J Cancer; 2004 Jan; 90(1):36-40. PubMed ID: 14710203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer.
    Spigel DR; Burstein HJ
    Clin Breast Cancer; 2003 Dec; 4(5):329-37; discussion 338-9. PubMed ID: 14715107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
    Brufsky A; Lembersky B; Schiffman K; Lieberman G; Paton VE
    Clin Breast Cancer; 2005 Aug; 6(3):247-52. PubMed ID: 16137436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
    Pegram MD; Lipton A; Hayes DF; Weber BL; Baselga JM; Tripathy D; Baly D; Baughman SA; Twaddell T; Glaspy JA; Slamon DJ
    J Clin Oncol; 1998 Aug; 16(8):2659-71. PubMed ID: 9704716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
    Seidman AD; Fornier MN; Esteva FJ; Tan L; Kaptain S; Bach A; Panageas KS; Arroyo C; Valero V; Currie V; Gilewski T; Theodoulou M; Moynahan ME; Moasser M; Sklarin N; Dickler M; D'Andrea G; Cristofanilli M; Rivera E; Hortobagyi GN; Norton L; Hudis CA
    J Clin Oncol; 2001 May; 19(10):2587-95. PubMed ID: 11352950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
    Chang HR
    Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.